Kenya Accelerates Vaccine Self-Sufficiency Drive as KEMRI Conference Showcases Breakthroughs in Research and Neonatal Health
By Irene
Kenya is steadily positioning itself as a continental leader in Africa’s ambition to achieve 60 percent vaccine self-sufficiency by 2040, with progress anchored under the Kenya Vision 2030 development blueprint.
Speaking at the 16th KEMRI Annual Scientific and Health (KASH) Conference, Vision 2030 Delivery Secretariat Director General Mr. Kenneth Mwige outlined milestones the country has achieved in strengthening local vaccine manufacturing, policy coordination, and health-sector investment. The conference, held under the theme “The Future of Health: Scientific Research, Innovations, Technologies and Manufacturing for a Resilient UHC,” brought together leading scientists, policymakers, and global health partners.
Mr. Mwige noted that sustained governance reforms, results-based planning, and strategic public–private partnerships have laid a firm foundation for technology transfer, industrial growth, and investment mobilization in Kenya’s health sector. He emphasized that Kenya’s long-term development planning — including alignment with the forthcoming post-Vision 2030 “Kenya @100” agenda — has created policy certainty and coordination mechanisms necessary to support vaccine production and broader health innovation.
“As Africa works toward reducing reliance on imported vaccines, Kenya’s experience demonstrates that strong institutions, coordinated delivery, and strategic partnerships are critical to building sustainable local manufacturing capacity,” he said.
Kenya’s progress reflects a broader continental push for resilience in health systems, particularly following lessons learned during recent global health emergencies that exposed vulnerabilities in supply chains.